- Home
- BTAI vs FTHM Comparison
BTAI vs FTHM Comparison
Compare BTAI & FTHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- FTHM
- Stock Information
- Founded
- BTAI 2017
- FTHM 2010
- Country
- BTAI United States
- FTHM United States
- Employees
- BTAI N/A
- FTHM N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- FTHM Real Estate
- Sector
- BTAI Health Care
- FTHM Finance
- Exchange
- BTAI Nasdaq
- FTHM Nasdaq
- Market Cap
- BTAI 48.3M
- FTHM 54.7M
- IPO Year
- BTAI 2018
- FTHM 2020
- Fundamental
- Price
- BTAI $2.07
- FTHM $1.52
- Analyst Decision
- BTAI Buy
- FTHM Strong Buy
- Analyst Count
- BTAI 5
- FTHM 1
- Target Price
- BTAI $32.80
- FTHM $2.50
- AVG Volume (30 Days)
- BTAI 1.0M
- FTHM 250.9K
- Earning Date
- BTAI 11-13-2025
- FTHM 11-11-2025
- Dividend Yield
- BTAI N/A
- FTHM N/A
- EPS Growth
- BTAI N/A
- FTHM N/A
- EPS
- BTAI N/A
- FTHM N/A
- Revenue
- BTAI $868,000.00
- FTHM $390,032,000.00
- Revenue This Year
- BTAI N/A
- FTHM $25.22
- Revenue Next Year
- BTAI $614.78
- FTHM $16.19
- P/E Ratio
- BTAI N/A
- FTHM N/A
- Revenue Growth
- BTAI N/A
- FTHM 19.16
- 52 Week Low
- BTAI $1.17
- FTHM $0.65
- 52 Week High
- BTAI $13.28
- FTHM $3.37
- Technical
- Relative Strength Index (RSI)
- BTAI 34.40
- FTHM 40.42
- Support Level
- BTAI $2.14
- FTHM $1.54
- Resistance Level
- BTAI $2.46
- FTHM $1.84
- Average True Range (ATR)
- BTAI 0.17
- FTHM 0.15
- MACD
- BTAI 0.00
- FTHM -0.00
- Stochastic Oscillator
- BTAI 2.64
- FTHM 9.09
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.